|1.||Joles, Jaap A: 5 articles (12/2010 - 05/2002)|
|2.||Goldschmeding, Roel: 5 articles (12/2010 - 05/2002)|
|3.||Géczy, Joseph: 4 articles (01/2006 - 07/2003)|
|4.||Braam, Branko: 3 articles (12/2010 - 06/2008)|
|5.||Famaey, Jean-Pierre: 3 articles (01/2006 - 07/2003)|
|6.||Messin, Roger: 3 articles (01/2006 - 07/2003)|
|7.||Dubois, Claude: 3 articles (01/2006 - 07/2003)|
|8.||Carreer-Bruhwyler, Fabienne: 3 articles (06/2005 - 07/2003)|
|9.||Lalmand, Jacques: 2 articles (06/2015 - 03/2014)|
|10.||Pirenne, Bruno: 2 articles (06/2015 - 03/2014)|
01/03/1980 - "We conclude that molsidomine is effective in preventing the symptoms of angina pectoris. "
05/01/1983 - "Molsidomine could prove useful in the treatment of angina pectoris. "
12/01/1984 - "Studies of the efficacy of molsidomine, previously performed on our service, demonstrated that a clear antianginal effect in the longterm treatment of angina pectoris could only be achieved with a regimen of the standard 2 mg dose when given six times daily. "
03/01/2014 - "Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial."
01/01/2006 - "Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies."
04/01/1989 - "Long-term treatment with molsidomin preparations produced general improvement in 84.4% of patients, as reflected in the reduction of the signs of heart failure as well as the rate and intensity of anginal attacks."
01/01/1986 - "[Efficacy of corvaton in the long-term ambulatory treatment of heart failure in patients with rheumatic heart lesions]."
01/01/1984 - "Two patients did not respond initially to molsidomine; one died, the other remained in functional Class III. Another patient who responded initially was improved for over two years but died in cardiac failure after 42 months' treatment. "
06/01/1998 - "The aim of the study was to estimate the influence of long-term treatment with molsidomine on structure, systolic function and neurohormonal parameters in patients with chronic heart failure (CHF). "
01/15/1993 - "In this trial we compared the efficiency of molsidomine given either orally or intravenously in patients suffering from congestive heart failure. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
01/01/1985 - "The antianginal efficacy of molsidomine (single oral dose of 2 mg), a new antianginal drug, was evaluated in 12 patients with coronary artery disease in a double-blind randomized placebo-controlled study by bicycle ergometry. "
09/01/1994 - "The long-term antihypertensive efficacy of molsidomine 8 mg bid was studied in 24 patients with coronary artery disease in a double-blind, placebo-controlled trial of 3 weeks duration. "
10/01/1984 - "The dose-effect relation and duration of action of 2 mg, 4 mg and 6 mg molsidomine on ischemic ST-segment depression in the exercise-ECG were determined in a randomized and double-blind acute study of 12 patients with confirmed coronary artery disease. "
02/01/2003 - "Molsidomine (Mol) is a drug used for the treatment of coronary artery disease. "
04/01/2000 - "Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease."
02/01/2012 - "• Molsidomine was effective in reducing both local and systemic oxidative stress, but did not prevent corporal fibrosis. "
09/05/2013 - "At a later stage molsidomine decreased significantly the extent of the inflammatory infiltrate, whose persistence exacerbates muscle damage: most of the remaining macrophages displayed characteristics of the transitional population, associated with reduced fibrosis and increased preservation of the muscle tissue. "
01/01/1992 - "The same measurements were performed in 15 patients with cirrhosis (group 2) under basal conditions, 1 then 2 hours after double-blind administration of either molsidomine (10 patients) or placebo (5 patients). "
01/01/1992 - "Molsidomine, a long acting vasodilator with antianginal properties, has been shown to decrease porto-hepatic pressure gradient in patients with cirrhosis. "
09/01/1991 - "After a 2 mg oral dose, molsidomine elimination half-life was prolonged in cirrhotic patients (13.1 +/- 10.0 h vs 1.2 +/- 0.2 h, P less than 0.01) because of a decrease in its apparent plasma clearance (CL/F) (39.8 +/- 31.9 ml h-1 kg-1 in patients with cirrhosis vs 590 +/- 73 ml h-1 kg-1 in volunteers). "
|5.||Coronary Disease (Coronary Heart Disease)
01/21/1977 - "[An improved exercise test in coronary-heart disease: effect of molsidomin on erogometrically controlled exercise (author's transl)]."
01/01/2002 - "A randomised blind cross-over trial with lead-in placebo period trial compared efficiency of retard ID and molsidomin in 65 EA patients with AH (group 1) and 40 normotensive patients with coronary heart disease (group 2). "
02/01/1987 - "[Ex vivo study of blood platelet activation in healthy subjects or coronary disease patients after oral intake of molsidomine]."
01/01/1985 - "The present study was carried out to establish whether the in vitro dissolution profile of the tablet was reflected in vivo, thus permitting prediction of plasma molsidomine levels in patients with coronary heart disease."
04/01/2003 - "SNP and molsidomine are drugs commonly used as nitrovasodilators in coronary heart disease. "
|3.||Nitric Oxide (Nitrogen Monoxide)
|4.||3-morpholino-sydnonimine (SIN 1)